A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects

Summary

This is a multi-center, randomized, investigator-blinded, calcipotriol and betamethasone dipropionate gel and vehicle-controlled phase 3 clinical study to evaluate the efficacy and safety of MC2-01 cream in the treatment of Chinese plaque psoriasis to assess the efficacy and safety of MC2-01 cream in Chinese subjects aged ≥ 18 years with plaque psoriasis. This study includes a screening period, a treatment period, and a safety follow-up period.

Timeline

Start

2025-12-26

Primary completion

2026-10-10

Completion

2026-12-17

Outcome

Met primary endpoint

release “MC2-01 in adult patients with plaque psoriasis in China. Huadong Medicine has stated that the study met its primary endpoint” mc2therapeutics.com ↗

Drugs

Indications